Johnson & Johnson has taken part in a round for BlackThorn Therapeutics, which is targeting neurobehavioural conditions like depression or obsessive compulsive disorder.
US-based clinical-stage biopharmaceutical company BlackThorn Therapeutics closed a $40m series A round on Thursday that featured Johnson & Johnson Innovation – JJDC, the corporate venturing arm of healthcare group Johnson & Johnson.
The round was led by venture capital firm Arch Venture Partners, with participation from life sciences real estate provider Alexandria Real Estate Equities, Altitude Life Science Ventures, Mercury Fund and an unnamed additional fund.
BlackThorn was founded by Arch Venture Partners in collaboration with several research institutes. It…
